AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsh, T. J.
Right arrow Articles by Wood, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, T. J.
Right arrow Articles by Wood, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2004, p. 2166-2172, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2166-2172.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration

Thomas J. Walsh,1* Mats O. Karlsson,2 Timothy Driscoll,3 Adriano G. Arguedas,4 Peter Adamson,5,6 Xavier Saez-Llorens,7 Ajay J. Vora,8 Antonio C. Arrieta,9 Jeffrey Blumer,6,10 Irja Lutsar,11 Peter Milligan,11 and Nolan Wood11

National Cancer Institute and,1 Pediatric Pharmacology Unit, National Institute of Child Health and Human Development,6 Bethesda, Maryland; Uppsala University, Uppsala, Sweden,2 Duke University Medical Center, Durham, North Carolina,3 Instituto Costarricense de Invetigaciones Clinicas and National Children's Hospital, San Jose, Costa Rica,4 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania,5 Hospital del Niños, Ciudad de Panama, Panama,7 Sheffield Children's Hospital, Sheffield,8 Pfizer Global Research and Development, Sandwich, Kent, United Kingdom,11 Children's Hospital of Orange County, Orange, California,9 University Hospitals of Cleveland, Cleveland, Ohio,10

Received 3 November 2003/ Returned for modification 12 December 2003/ Accepted 4 February 2004

We conducted a multicenter study of the safety, tolerability, and plasma pharmacokinetics of the parenteral formulation of voriconazole in immunocompromised pediatric patients (2 to 11 years old). Single doses of 3 or 4 mg/kg of body weight were administered to six and five children, respectively. In the multiple-dose study, 28 patients received loading doses of 6 mg/kg every 12 h on day 1, followed by 3 mg/kg every 12 h on day 2 to day 4 and 4 mg/kg every 12 h on day 4 to day 8. Standard population pharmacokinetic approaches and generalized additive modeling were used to construct the structural pharmacokinetic and covariate models used in this analysis. In contrast to that in adult healthy volunteers, elimination of voriconazole was linear in children following doses of 3 and 4 mg/kg every 12 h. Body weight was more influential than age in accounting for the observed variability in voriconazole pharmacokinetics. Elimination capacity correlated with the CYP2C19 genotype. Exposures were similar at 4 mg/kg every 12 h in children (median area under the concentration-time curve (AUC), 14,227 ng · h/ml) and 3 mg/kg in adults (median AUC, 13,855 ng · h/ml). Visual disturbances occurred in 5 (12.8%) of the 39 patients and were the only drug-related adverse events that occurred more than once. No withdrawals from the study were related to voriconazole. We conclude that pediatric patients have a higher capacity for elimination of voriconazole per kilogram of body weight than do adult healthy volunteers and that dosages of 4 mg/kg may be required in children to achieve exposures consistent with those in adults following dosages of 3 mg/kg.

* Corresponding author. Mailing address: Pediatric Oncology Branch, National Cancer Institute, Bldg. 10, Rm. 13N240, Bethesda, MD 20892. Phone: (301) 496-7103. Fax: (301) 402-0575. E-mail: walsht{at}mail.nih.gov.

Antimicrobial Agents and Chemotherapy, June 2004, p. 2166-2172, Vol. 48, No. 6
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.6.2166-2172.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.